Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Hot Flashes 1Depression 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 9Psychiatric Rehabilitation 7Therapeutics 2Interviews as Topic 2Chemotherapy, Adjuvant 2pegfilgrastim 1enzalutamide 1darolutamide 1apalutamide 1Vortioxetine 1Venlafaxine Hydrochloride 1Transurethral Resection of Prostate 1Thyroidectomy 1Tamoxifen 1Standard of Care 1Single Person 1Sertraline 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Physical Examination 1Palliative Care 1Observation 1Models, Nursing 1Metformin 1Mental Status and Dementia Tests 1Granulocyte Colony-Stimulating Factor 1Genetic Testing 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Depression × Escitalopram × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡